Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $925.00

Key Points

• Wells Fargo raised Regeneron’s price target from $750 to $925 while maintaining an “equal weight” rating, implying roughly 0.31% downside from the $927.89 share price. The analyst consensus remains “Moderate Buy,” with an average target of $878.03.
• Regeneron reported strong quarterly results, with EPS of $20.07 exceeding the $16.51 consensus estimate and revenue of $5.12 billion surpassing the $4.58 billion forecast. Revenue increased 36.3% year over year, supported by continued growth in Dupixent.
• The stock is trading near its 52-week high of $935.35, raising potential valuation and profit-taking risks after its strong rally. Insiders sold about $6.5 million of shares over the past 90 days, although institutional investors own 83.31% of the company.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective upped by investment analysts at Wells Fargo & Company from $750.00 to $925.00 in a research report issued on Monday, Benzinga reports. The brokerage presently has an "equal weight" rating on the biopharmaceutical company's stock. Wells Fargo & Company's price objective suggests a potential downside of 0.31% from the company's current price.

Several other research firms have also recently weighed in on REGN. The Goldman Sachs Group increased their price objective on shares of Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Sunday, September 20th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Benchmark raised shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Finally, Argus upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating and set a $850.00 target price on the stock in a research note on Thursday, October 1st. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $878.03.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN opened at $927.89 on Monday. Regeneron Pharmaceuticals has a one year low of $591.52 and a one year high of $935.35. The stock has a market capitalization of $95.54 billion, a PE ratio of 20.49, a price-to-earnings-growth ratio of 1.57 and a beta of 0.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company's 50-day moving average price is $793.30 and its two-hundred day moving average price is $738.05.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, beating the consensus estimate of $16.51 by $3.56. The firm had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company's quarterly revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the company earned $11.83 earnings per share. On average, equities analysts forecast that Regeneron Pharmaceuticals will post 49.10 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Kathryn Guarini sold 400 shares of the company's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the transaction, the director owned 603 shares in the company, valued at approximately $512,550. This represents a 39.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Western Wealth Management LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $26,000. Armstrong Advisory Group Inc. lifted its holdings in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $29,000. Trust Co. of Vermont purchased a new position in Regeneron Pharmaceuticals in the second quarter worth about $29,000. Finally, Fiduciary Financial Advisors bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $29,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
• Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
• Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
• Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
• Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.